Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Abroad (travel likely)RecruitingPHASE2
Conditions
Lung Cancer Non-Small Cell Cancer (NSCLC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Hospital Freiburg, Freiburg im Breisgau, Baden-Wurttemberg, Germany
Contact: Study coordinator (Cornelius Waller, Prof. Dr. med.) · cornelius.waller@uniklinik-freiburg.de · 0049 761 270 34220Klinikum Stuttgart, Stuttgart, Baden-Wurttemberg, Germany
Contact: Study coordinator (Marc Münter, Prof. Dr. med.) · sekretariat.muenter@klinikum-stuttgart.de · 0049 711 278 34201University Hospital Gießen, Giessen, Hesse, Germany
Contact: Study coordinator (Thomas Wehler, Prof. Dr. med.) · oon.studienzentrum@uk-gm.de · 0049 641 98543501Johannes Wesling Klinikum Minden Mühlenkreiskliniken, Hämatologie und Onkologie, Minden, North Rhine-Westphalia, Germany
Contact: Study coordinator (Parvis Sadjadian, Dr. med.) · haematologie-onkologie@muehlenkreiskliniken.de · 0049 05 71 / 7 90 42 01University Hospital Bonn, Bonn, Germany